Tel +1.201.308.8775
E-mail njadmin@njipla.org

New Jersey Intellectual Property Law Association (NJIPLA)
c/o RRR Associations, LLC
2125 Center Avenue, Suite 406, Fort Lee, NJ, 07024

Structuring Biotech & Pharma Startup Portfolios for Global Impact, Value, and Partnering

  • 10/21/2020
  • 2:00 PM - 3:00 PM
  • GoToWebinar

Registration


Register

34th Annual Pharmaceutical/Chemical Patent Practice Update Webinar SeriesEarn up to 1.0 Professional CLE for NJ/NY

With continued significant investment by venture, PE, and pharma communities in biotech clusters around the world, ensuring that your portfolio can provide maximum value on a global scale for ultimate partnering or acquisition is a crucial element of any startup’s strategic plan. Teresa will discuss important considerations such as: Balancing early filing/first to file realities with meeting enablement and support requirements in the US and around the world; best practices for working with CROs, consultants, and universities; and details such as inventorship, ownership, and chain of title.

Speaker Teresa A. Lavoie, Fish & Richardson
Dr. Teresa Lavoie has developed, managed, and overseen the sale of patent portfolios worth more than $33 billion in deal value. Her international practice focuses on strategic patent counseling, prosecution, and portfolio development advice, including patent opinions, due diligence, freedom-to-operate analyses, and life cycle management strategies. Dr. Lavoie’s clients range from start-up and emerging companies developing life-saving therapeutics and diagnostics to academic and research institutions inventing disruptive platform technologies for the biotechnology and biopharma industries. She has extensive experience in the areas of small-molecule and biologic pharmaceuticals (including antibody technologies and immunotherapies, such as CAR-T therapies), drug formulation and drug delivery technologies, diagnostics, clean and alternative (animal- and environmentally-friendly) food technologies, protein biochemistry and engineering, cell systems engineering, nanotechnologies, plant biotechnology and genomics, and green/environmental chemistries. Dr. Lavoie also has significant transactional experience in various aspects of IP licensing, including sponsored research, feasibility, and development and commercialization agreements. [Read more]

Moderators J. Eric Thies, Merck & Co., Inc. and Suja Vathyam, Botos Churchill IP Law LLP

GoToWebinar Note: Once you register, you will receive a GoToWebinar confirmation e-mail with a unique link to join the session. Click "Add to calendar" to ensure you don't miss the webinar.

Chemical Practice Co-Chairs J. Eric Thies, Merck & Co., Inc. and Suja Vathyam, Botos Churchill IP Law LLP